In recent years, to improve the tumor targetability of iPSCs-derived T cells, the combination of iPSCs generation technology with the transduction of tumor antigen-specific T cell receptors (TCRs) or chimeric antigen receptors (CARs) has become an effective strategy for generating tumor-specific T cells [71]. This evidence concerns the gene CARS1 and neoplasm.